glp 1 cirrhosis GLP-1 and fatty liver disease. Non-alcoholic fatty liver disease affects 25% of adults worldwide. It is directly linked to excess weight and insulin resistance. Left untreated, it can progress to and GLP-1s Gain Ground in Liver
Description
The weight loss was a fortuitous side effect because semaglutide was originally designed to be a treatment for diabetes
This equates to a 418 decline in per household spend when compared to non-user households
it results in $147 billion in health care spending annually (204)
Symptom timeline
Faster protocols also mean less total time exposed to the gastrointestinal side effects that accompany all incretin therapies
